Dr. Rogers Discusses Obinutuzumab, Ibrutinib, and Venetoclax Combination in CLL

In Partnership With:

Partner | Cancer Centers | <b>The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research Institute (OSUCCC - James)</b>

Kerry Rogers, MD, assistant professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the initial results of the phase II treatment-naïve cohort in a phase Ib/II study of obinutuzumab (Gazyva), ibrutinib (Imbruvica), and venetoclax (Vencelxta) in chronic lymphocytic leukemia (CLL).

Kerry Rogers, MD, assistant professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the initial results of the phase II treatment-naïve cohort in a phase Ib/II study of obinutuzumab (Gazyva), ibrutinib (Imbruvica), and venetoclax (Venclexta) in chronic lymphocytic leukemia (CLL).

This study investigates a chemotherapy-free combination, explains Rogers. Traditionally, there has been success with chemotherapy combination treatments. However, side effects of chemotherapy are difficult for many patients.

According to Rogers, these 3 agents have different mechanisms of action and non-overlapping toxicity profiles, making them an interesting combination to study.